Electrophysiological determination of phosphodiesterase-6 inhibitor inhibition constants in intact mouse retina

Closed-Perfusion Transretinal ERG Setup for Preclinical Drug and Nanostructure Testing

OBJECTIVE

The isolated mammalian retina may serve as a sensitive biosensor for preclinical drug testing, including eye drugs and a broader range of pharmaceuticals. To facilitate testing with minimal amounts of drug molecules or nanostructures, we developed a closed-perfusion transretinal electroretinography (tERG) setup.

METHODS

The major challenge with small amounts of circulating perfusate was maintaining retinal viability and stability during long experiments. We conducted ex vivo tERG using WT C57BL/6J and mice to assess rod- and cone-mediated light signals. The dark-adapted retina was stimulated with full-field light flashes while perfused at 5-6 ml/min.

RESULTS

The minimum perfusate needed in our closed-circulation was around 50 ml. Penicillin-Streptomycin (Pen-Strep) was indispensable for long recordings. Rod responses remained stable for at least 42 hours, the longest recording we conducted, with the retina still responsive, and rod and cone bipolar cell responses for up to 12 hours. IBMX (3-isobutyl-1-methylxanthine), a non-specific phosphodiesterase (PDE) inhibitor with reversible effects, validated our setup. We used our setup to test the zwitterionic polymer poly(sulfobetaine methacrylate) (PSMBA), serving as a promising material for thermoresponsive nanostructures, and the corresponding monomer SBMA for possible harmful effects on mouse rod and bipolar cell functioning.

CONCLUSION

Our closed-perfusion tERG setup enables long experiments with small amounts of perfusate. PSMBA or SBMA had no effect on rod and bipolar cell responses.

SIGNIFICANCE

This method is applicable for assessing drug functionality, as well as conducting preliminary biocompatibility and toxicity testing using small amounts of molecules or nanostructures that could impact neuronal or synaptic function.

A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6

CB-5083 is an inhibitor of p97/valosin-containing protein (VCP), for which phase I trials for cancer were terminated because of adverse effects on vision, such as photophobia and dyschromatopsia. Lower dose CB-5083 could combat inclusion body myopathy with early-onset Paget disease and frontotemporal dementia or multisystem proteinopathy caused by gain-of-function mutations in VCP. We hypothesized that the visual impairment in the cancer trial was due to CB-5083's inhibition of phosphodiesterase (PDE)-6, which mediates signal transduction in photoreceptors. To test our hypothesis, we used in vivo and ex vivo electroretinography (ERG) in mice and a PDE6 activity assay of bovine rod outer segment (ROS) extracts. Additionally, histology and optical coherence tomography were used to assess CB-5083's long-term ocular toxicity. A single administration of CB-5083 led to robust ERG signal deterioration, specifically in photoresponse kinetics. Similar recordings with known PDE inhibitors sildenafil, tadalafil, vardenafil, and zaprinast showed that only vardenafil had as strong an effect on the ERG signal in vivo as did CB-5083. In the biochemical assay, CB-5083 inhibited PDE6 activity with a potency higher than sildenafil but lower than that of vardenafil. Ex vivo ERG revealed a PDE6 inhibition constant of 80 nM for CB-5083, which is 7-fold smaller than that for sildenafil. Finally, we showed that the inhibitory effect of CB-5083 on visual function is reversible, and its chronic administration does not cause permanent retinal anomalies in aged VCP-disease model mice. Our results warrant re-evaluation of CB-5083 as a clinical therapeutic agent. We recommend preclinical ERG recordings as a routine drug safety screen. SIGNIFICANCE STATEMENT: This report supports the use of a valosin-containing protein (VCP) inhibitor drug, CB-5083, for the treatment of neuromuscular VCP disease despite CB-5083's initial clinical failure for cancer treatment due to side effects on vision. The data show that CB-5083 displays a dose-dependent but reversible inhibitory action on phosphodiesterase-6, an essential enzyme in retinal photoreceptor function, but no long-term consequences on retinal function or structure.

Functional modulation of phosphodiesterase-6 by calcium in mouse rod photoreceptors

Phosphodiesterase-6 (PDE6) is a key protein in the G-protein cascade converting photon information to bioelectrical signals in vertebrate photoreceptor cells. Here, we demonstrate that PDE6 is regulated by calcium, contrary to the common view that PDE1 is the unique PDE class whose activity is modulated by intracellular Ca²⁺. To broaden the operating range of photoreceptors, mammalian rod photoresponse recovery is accelerated mainly by two calcium sensor proteins: recoverin, modulating the lifetime of activated rhodopsin, and guanylate cyclase-activating proteins (GCAPs), regulating the cGMP synthesis. We found that decreasing rod intracellular Ca²⁺ concentration accelerates the flash response recovery and increases the basal PDE6 activity (β_dark) maximally by ~ 30% when recording local electroretinography across the rod outer segment layer from GCAPs^-/- recoverin^-/- mice. Our modeling shows that a similar elevation in β_dark can fully explain the observed acceleration of flash response recovery in low Ca²⁺. Additionally, a reduction of the free Ca²⁺ in GCAPs^-/- recoverin^-/- rods shifted the inhibition constants of competitive PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) against the thermally activated and light-activated forms of PDE6 to opposite directions, indicating a complex interaction between IBMX, PDE6, and calcium. The discovered regulation of PDE6 is a previously unknown mechanism in the Ca²⁺-mediated modulation of rod light sensitivity.

Cyclic nucleotide phosphodiesterases: New targets in the metabolic syndrome?

Metabolic diseases have a tremendous impact on human morbidity and mortality. Numerous targets regulating adenosine monophosphate kinase (AMPK) have been identified for treating the metabolic syndrome (MetS), and many compounds are being used or developed to increase AMPK activity. In parallel, the cyclic nucleotide phosphodiesterase families (PDEs) have emerged as new therapeutic targets in cardiovascular diseases, as well as in non-resolved pathologies. Since some PDE subfamilies inactivate cAMP into 5'-AMP, while the beneficial effects in MetS are related to 5'-AMP-dependent activation of AMPK, an analysis of the various controversial relationships between PDEs and AMPK in MetS appears interesting. The present review will describe the various PDE families, AMPK and molecular mechanisms in the MetS and discuss the PDEs/PDE modulators related to the tissues involved, thus supporting the discovery of original molecules and the design of new therapeutic approaches in MetS.

Determination of basal phosphodiesterase activity in mouse rod photoreceptors with cGMP clamp

Light regulates cGMP concentration in the photoreceptor cytoplasm by activating phosphodiesterase (PDE) molecules through a G-protein signalling cascade. Spontaneous PDE activity is present in rod outer segments even in darkness. This basal PDE activity (β_dark) has not been determined in wild type mammalian photoreceptor cells although it plays a key role in setting the sensitivity and recovery kinetics of rod responses. We present a novel method for determination of β_dark using local electroretinography (LERG) from isolated mouse retinas. The method is based on the ability of PDE inhibitors to decrease β_dark, which can be counterbalanced by increasing PDE activity with light. This procedure clamps cytoplasmic cGMP to its dark value. β_dark can be calculated based on the amount of light needed for the "cGMP clamp" and information extracted from the registered rod photoresponses. Here we apply this method to determine β_dark values for the first time in the mammalian rods and obtain the following estimates for different mouse models: 3.9 s^-1 for wild type, 4.5 s^-1 for guanylate cyclase activating proteins (GCAPs) knockout, and 4.4 s^-1 for GCAPs and recoverin double knockout mice. Our results suggest that depletion of GCAPs or recoverin do not affect β_dark.